oAlert.pl

Medicines & supplements – Current GIS Alerts 2026

Found 774 alerts in the Medicines & supplements category. Check batch numbers, shops, and hazard information.

Common hazards in this category

All recalled products

Recalled product: Envil gardło

Envil gardło

GIF Low 10.09.2026

Stability testing showed an ethanol content below the specification limit, so the efficacy and safety of continued use of the batch cannot be confirmed. Potential effects: possible lack of efficacy or unpredictable product performance.

Recalled product: Fluoksetyna EGIS

Fluoksetyna EGIS

GIF Medium 09.09.2026

The stability study showed active substance content below the specification limit. The lower content may result in lower-than-expected product efficacy. Potential effects: possible reduction in therapeutic efficacy.

Recalled product: Fluorouracil Accord

Fluorouracil Accord

GIF Critical 03.09.2026

A slight exceedance of the limit for a single unknown impurity was found in a long-term stability study. No impact on the product's quality, safety or efficacy was identified. Potential effects: low risk to patient safety.

Recalled product: Loperamid APTEO MED

Loperamid APTEO MED

GIF Medium 31.08.2026

A quality defect was identified: active substance content in capsules is lower than declared, caused by instability of the manufacturing process, which may result in lack of the intended efficacy of the medicinal product. Potencjalne skutki: lack of effectiveness in treating diarrhoea.

Recalled product: Creatine Xplode Powder

Creatine Xplode Powder

- Medium 27.08.2026 • Auchan

The withdrawal is due to uncertainty about the regulatory status of creatine malate as a novel food ingredient, which is currently being verified by the sanitary authorities. Potential effects: Possible unknown health risks associated with long-term use.

Recalled product: Dutilox

Dutilox

GIF Critical 25.08.2026

Serious exceedance of the transitional LTL limit for N-nitroso-duloxetine contamination during the declared shelf life of the medicine, posing a risk to public health and potentially to patients' lives. Potencjalne skutki: increased risk of cancer and other serious adverse effects.

Recalled product: Dutilox

Dutilox

GIF High 25.08.2026

A public health risk was identified due to a serious exceedance of the transitional LTL limit for the impurity N-nitroso-duloxetine within the declared shelf life of the medicinal product. Potential effects: increased risk of adverse reactions, including possible carcinogenic effects with long-term use.

Recalled product: TREC Nutrition CM3 and 6PAK CrM3 dietary supplements

TREC Nutrition CM3 and 6PAK CrM3 dietary supplements

- Medium 24.08.2026 • Auchan

Tricreatine malate has been recognised as unauthorised novel food. This ingredient has not undergone a full safety assessment by EFSA and has not obtained authorisation from the European Commission. Potential effects: Uncertain safety of tricreatine malate use due to the lack of a full risk assessment.

Recalled product: Fingolimod Zentiva

Fingolimod Zentiva

GIF Critical 19.08.2026

Failure to meet quality requirements due to exceeding acceptance limits for the number of detected metal particles in batch 4L01372M; the presence of metal particles prevents confirmation of the safety of further use of this batch. Potential effects: irritation, tissue damage, thrombotic complications or other adverse effects related to the presence of metal particles.

Recalled product: Syrop tymiankowy złożony Ziołowa Tradycja

Syrop tymiankowy złożony Ziołowa Tradycja

GIF Low 17.08.2026

In this case there is a non-compliance in the content of thymol, consisting of a lower amount of this component than required by the specification limit and out-of-specification results in stability testing. Potencjalne skutki: reduced effectiveness of cough treatment.

Recalled product: Soltopin

Soltopin

GIF High 12.08.2026

Stability studies showed a reduced content of active substance and levels of impurities above the acceptable limits, including Mupirocin I and unidentified impurities; the efficacy and safety of further use of this batch cannot be confirmed. Potential effects: lack of treatment efficacy, undefined adverse effects.

Recalled product: Levosimendan Farmak

Levosimendan Farmak

GIF Critical 05.08.2026

Testing by the National Medicines Institute showed contamination of the product with particles visible to the naked eye in 12 of 20 tested vials, meaning failure to meet quality specifications for infusion solutions. Potential effects: thromboembolic complications, inflammatory reactions, unsafe intravenous treatment.

Recalled product: Adnamil

Adnamil

GIF Low 31.07.2026

Tests showed non-compliance with quality requirements for the parameters "Appearance" and "Resistance to crushing" ("Hardness"), as well as dust on tablets in blisters and hardness values exceeding the upper specification limit. Potencjalne skutki: abnormal release of the active substance or reduced treatment efficacy.

Recalled product: Atorvastatin Medical Valley

Atorvastatin Medical Valley

GIF Medium 31.07.2026

The product does not comply with quality requirements due to a failed appearance test; this quality defect may affect critical quality attributes of the medicinal product, especially during storage. Potential effects: reduced treatment efficacy, variability in drug action, possible adverse reactions.

Recalled product: Concor Cor 5

Concor Cor 5

GIF Critical 24.07.2026

Stability studies showed an exceedance of the quality specification limit for the N-Nitroso-Bisoprolol (NBP) impurity content; further increase of this impurity level is expected during the product's shelf life. Potential effects: possible carcinogenic effects and complications from long-term exposure to a nitrosamine impurity.

Recalled product: Concor Cor 5

Concor Cor 5

GIF Critical 24.07.2026

An exceedance of the quality specification limit for the content of the impurity N-Nitroso-Bisoprolol (NBP) was found in Concor Cor 5 mg tablets, with a tendency for further increase of this impurity level during the product's shelf-life. Potential effects: possible toxic and carcinogenic effects, especially with long-term use.

Recalled product: Concor 5

Concor 5

GIF High 24.07.2026

A breach of the quality specification limit was found for the content of the N-Nitroso-Bisoprolol (NBP) impurity in 5 mg bisoprolol fumarate tablets, indicating the presence of an undesired nitrosamine impurity forming during storage of the medicine. Potential effects: increased carcinogenic risk with long-term use of the medicine.

Recalled product: Concor Cor 5

Concor Cor 5

GIF High 24.07.2026

The non-compliance consists in exceeding the quality specification limit for the content of the impurity N-Nitroso-Bisoprolol (NBP), which increases during storage of the tablets. Potential effects: increased risk of adverse reactions, including potential carcinogenic effects with long-term use.

Recalled product: Concor 5

Concor 5

GIF High 24.07.2026

The non-compliance consists in exceeding the specification limit for the content of the impurity N-nitroso-bisoprolol. Assessment of available stability data indicates that NBP will continue to form during the shelf-life. Potential effects: increased risk of carcinogenic effects with long-term use.

Recalled product: Concor Cor 5

Concor Cor 5

GIF High 23.07.2026

The non-compliance consists in exceeding the quality specification limit for the content of the impurity N-nitroso-bisoprolol (NBP) in the finished film-coated tablets. Potencjalne skutki: increased risk of carcinogenic effects during long-term use of the medicine.

What to do if you bought a recalled product?

If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.